Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
|Articles|April 15, 2020
VIDEO SPECIAL: The Cardiac Dangers of Hydroxychloroquine and Azithromycin
Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.
Advertisement
Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.
Advertisement
Related to this article
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
3
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
4
Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy
5